Acknowledging this limitation, the strong and robust response across these lines, which carry commonly recurring T-ALL mutations, suggests that human trials for idasanutlin and navitoclax combination therapy in wildtype TP53 cases are merited. Here, TP53 is linked to acute lymphoblastic leukemia.